StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Beam Therapeutics's total assets was $1.39B at Jun 30, 2026. For fiscal 2025 it was $1.48B, up 34.2% from the year before. The highest annual figure on record is $1.48B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.48B+34.2%
FY2024Dec 31, 2024$1.10B-24.4%
FY2023Dec 31, 2023$1.46B+8.8%
FY2022Dec 31, 2022$1.34B-9.0%
FY2021Dec 31, 2021$1.47B+226.4%
FY2020Dec 31, 2020$451.68M+189.4%
FY2019Dec 31, 2019$156.10M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.39B-0.3%
Q1 FY2026Mar 31, 2026$1.48B+0.9%
Q4 FY2025Dec 31, 2025$1.48B+34.2%
Q3 FY2025Sep 30, 2025$1.31B+11.9%
Q2 FY2025Jun 30, 2025$1.39B+10.3%
Q1 FY2025Mar 31, 2025$1.47B+7.9%
Q4 FY2024Dec 31, 2024$1.10B-24.4%
Q3 FY2024Sep 30, 2024$1.17B-9.2%
Q2 FY2024Jun 30, 2024$1.26B-6.8%
Q1 FY2024Mar 31, 2024$1.36B+2.1%
Q4 FY2023Dec 31, 2023$1.46B+8.8%
Q3 FY2023Sep 30, 2023$1.29B-4.4%
Q2 FY2023Jun 30, 2023$1.35B-4.5%
Q1 FY2023Mar 31, 2023$1.33B-8.3%
Q4 FY2022Dec 31, 2022$1.34B-9.0%
Q3 FY2022Sep 30, 2022$1.35B+16.7%
Q2 FY2022Jun 30, 2022$1.42B+58.8%
Q1 FY2022Mar 31, 2022$1.45B+109.7%
Q4 FY2021Dec 31, 2021$1.47B+226.4%
Q3 FY2021Sep 30, 2021$1.16B+315.6%
Q2 FY2021Jun 30, 2021$893.08M+197.7%
Q1 FY2021Mar 31, 2021$693.24M+114.9%
Q4 FY2020Dec 31, 2020$451.68M+189.4%
Q3 FY2020Sep 30, 2020$278.27M–
Q2 FY2020Jun 30, 2020$299.98M–
Q1 FY2020Mar 31, 2020$322.64M–
Q4 FY2019Dec 31, 2019$156.10M–

More Beam Therapeutics figures

See a number that looks wrong?